A synergistic GHRH + GHRP combination for enhanced GH pulsatility and visceral fat reduction.
This combination pairs Tesamorelin (GHRH analog) with Ipamorelin (GHRP) for synergistic GH release. Tesamorelin provides the GHRH stimulus while Ipamorelin amplifies the GH pulse through GHS-R1a, resulting in greater GH secretion than either alone.
Subcutaneous injection
0.75 mg to 2.25 mg
Daily (bedtime preferred)
“A synergistic GHRH + GHRP combination for enhanced GH pulsatility and visceral fat reduction.”
Tesamorelin activates GHRH receptors to stimulate GH synthesis. Ipamorelin activates GHS-R1a to amplify the GH pulse. The dual mechanism produces 3–5x greater GH release than either peptide alone.
0.75 mg to 2.25 mg
Daily (bedtime preferred)
8–16 weeks
Subcutaneous injection
Administer on empty stomach. Bedtime dosing maximizes natural GH pulse. Monitor IGF-1 levels every 3 months.
Per prescriber instructions.
Lyophilized: refrigerate. Reconstituted: refrigerate and use within 30 days.
When sourcing Tesamorelin / Ipamorelin for research purposes, the following quality benchmarks should be verified before use.
>98% (verified by HPLC)
Must be provided by supplier
<0.1 EU/mg (prevents bacterial contamination)
Manufactured in cGMP-certified facility
Independent lab verification preferred
Lyophilized: refrigerate. Reconstituted: refrigerate and use within 30 days.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.
Multiple animal studies and/or early human trials. Reasonable confidence in mechanism, but human data is limited.
Peptides commonly used alongside Tesamorelin / Ipamorelin / MGF for synergistic effects.
A synthetic pentadecapeptide derived from gastric juice with extraordinary tissue healing properties across multiple organ systems.
A synthetic analog of Thymosin Beta-4 that promotes systemic healing through actin regulation and angiogenesis.
Category
Status
Dose
0.75 mg to 2.25 mg
Frequency
Daily (bedtime preferred)
Cycle
8–16 weeks
Peptides
Protocols
Other Pages
Contact Us Today!
© 2026 Best Health IQ. All rights reserved.
FDA Disclaimer: The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many compounds described on this site are not approved by the FDA for human therapeutic use. Some are available only as compounded preparations or as materials sold for laboratory use, and several are on FDA's Category 2 list for significant safety risks. Nothing on this site constitutes medical advice or a recommendation to use any compound described.
